Oxygen Biotherapeutics has dismissed Chris Stern as chief executive officer (CEO) and chairman and has named Michael Jebsen as interim CEO. Jebsen will retain his positions as chief financial officer (CFO) and treasurer.
Jebsen has served as Oxygen’s CFO, secretary and treasurer since August 2009 and has a thorough understanding of Oxygen’s day-to-day business operations, overall strategic plan and financial situation. He first joined Oxygen as its accounting manager in April 2009, and was elected CFO, executive vice president (EVP) finance and administration, corporate secretary and treasurer in August 2009. Before joining Oxygen, he was an auditor with Grant Thornton, LLP from July 2003 through December 2005 and from April 2008 through April 2009.
In addition, Jebsen held various positions, including chief ethics officer, senior internal auditor and senior financial analyst with RTI International, a non-profit research and development organisation, from January 2006 to February 2008. He holds an MSc in Accounting from East Carolina University and is a certified public accountant (CPA), licensed in North Carolina.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.